Zobrazeno 1 - 10
of 115
pro vyhledávání: '"C, Rotellar"'
Autor:
Mary Jane Mauoni, William P. Argy, Elwin Bustos, Thomas A. Rakowski, C Rotellar, James F. Winchester
Publikováno v:
Seminars in Dialysis. 7:355-359
Autor:
Marylynn Amiranzavi, Vincent F. Garagusi, John Black, Winnie F. Mosher, C Rotellar, William P. Argy, Mohammad R. Alijani, Mary Jane Mazzoni, James F. Winchester, Thomas A. Rakowski
Publikováno v:
American Journal of Kidney Diseases. 17:158-164
Up to January 1989, 171 patients were trained at our center on continuous ambulatory peritoneal dialysis (CAPD), and 17 on continuous cyclic peritoneal dialysis (CCPD). Over 10 years, we have gained 5,068 patient-months experience. Patient survival w
Autor:
James F. Winchester, William P. Argy, M J Mazzoni, W F Mosher, S Sivarajan, Thomas A. Rakowski, C Rotellar, M Aminrazavi
Publikováno v:
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 12:396-398
Publikováno v:
Kidney international. Supplement. 41
Publikováno v:
Kidney international. Supplement. 40
Autor:
C, Rotellar, V, Kinsel, M, Goggins, G, Tarman, M, Stull, M J, Mazzoni, W F, Mosher, T A, Rakowski, J F, Winchester
Publikováno v:
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 13
A lower-calcium dialysate has been advocated for continuous ambulatory peritoneal dialysis (CAPD) patients for the purpose of increasing oral calcium intake as a phosphate binder and decreasing the need for aluminum-containing phosphate binders and,
Autor:
C, Rotellar, S, Sivarajan, M J, Mazzoni, M, Aminrazavi, W F, Mosher, T A, Rakowski, W P, Argy, J F, Winchester
Publikováno v:
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. 12(4)
Publikováno v:
Contributions to nephrology. 89
Autor:
S Sims, C Rotellar
Publikováno v:
Journal of the American Society of Nephrology. 6:136-137
Publikováno v:
Nephron. 41:152-156
This manuscript consists of a study of the results of 26 end stage renal failure (ESRF) patients, who commenced regular haemodialysis treatment (RHDT) from the age of 65 onwards (65-85) and who have been undergoing this treatment for periods ranging